Aurobindo Pharma Ltd
NSE: AUROPHARMA · Pharmaceuticals · sector
₹1,590.00NSE close 2026-10-26
Key numbers
Market cap₹91,489 cr
Price₹1,590.00
52w high / low₹1,740 / ₹1,080
P/E24.9xSector median 27.9x
P/B2.4xSector median 2.9x
Book value₹658.5
Dividend yield0.26%Sector median 0.48%
ROE10.5%Sector median 11.7%
ROCE12.8%Sector median 12.3%
OPM20.0%Sector median 14.0%
Debt / equity0.20xSector median 0.16x
EV/EBITDA12.7xSector median 18.6x
Interest cover15.0x
Current ratio1.81x
Sales growth 3y+10.6%Sector median +9.6%
Profit growth 3y+22.1%Sector median +13.3%
PEG1.11x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹10,618 cr vs borrowings ₹7,676 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 15.0x in the last 12 months.
- 11.99% of the promoters' shares are pledged (6.2% of all shares).
- Operating cash flow was below net profit in 1 of the last 5 years (FY24).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 19% of net profit in the last 12 months.
- Debtor days went from 61 (FY24) to 77 (FY26).
- Dividend paid in 4 of the last 5 financial years.
- Price ₹1,590.00 on 2026-10-26: -8.6% from the 52-week high, +47.2% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹1,716.00 · low ₹1,026.30
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 | 8,646 | 8,853 | 9,150 |
| EBITDA | 1,566 | 1,578 | 1,792 | 1,603 | 1,678 | 1,708 | 1,753 | 1,841 |
| OPM % | 20.1% | 19.8% | 21.4% | 20.4% | 20.3% | 19.8% | 19.8% | 20.1% |
| Other income | 136 | 157 | 135 | 105 | 121 | 188 | 117 | 264 |
| Net profit | 817 | 855 | 903 | 825 | 848 | 910 | 921 | 1,033 |
| EPS (₹) | 14.00 | 14.56 | 15.56 | 14.20 | 14.61 | 15.67 | 15.86 | 17.86 |
| Revenue YoY | +6.3% | +8.4% | +5.6% | +16.3% | ||||
| Profit YoY | +3.8% | +6.5% | +2.0% | +25.2% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 23,455 | 24,855 | 29,002 | 31,724 | 33,653 | 34,935 |
| EBITDA | 4,259 | 3,719 | 5,651 | 6,583 | 6,780 | 6,980 |
| Net profit | 2,648 | 1,928 | 3,173 | 3,486 | 3,505 | 3,713 |
| EPS (₹) | 45.19 | 32.90 | 54.16 | 59.81 | 60.34 | 64.00 |
| Revenue growth | +6.0% | +16.7% | +9.4% | +6.1% | +9.1% | |
| Profit growth | -27.2% | +64.6% | +9.9% | +0.5% | +9.2% | |
| Dividend / share (₹) | 4.50 | 7.50 | 4.50 | – | 4.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +10.6% | +6.3% | +9.1% |
| Net profit | +22.1% | -8.1% | +9.2% |
| EPS | +22.4% | -7.9% | – |
| Share price | – | +4.0% (2y) | +43.5% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 26,840 | 29,843 | 32,653 | 37,891 |
| Borrowings | – | 4,862 | 6,315 | 7,942 | 7,676 |
| Cash & equivalents | – | 6,235 | 6,329 | 8,236 | 10,618 |
| Total assets | – | 39,890 | 45,072 | 49,785 | 58,502 |
| Fixed assets | – | 7,995 | 11,546 | 12,189 | 14,330 |
| Capital work in progress | – | 4,496 | 2,739 | 3,266 | 3,009 |
| Investments | – | 302 | 227 | 206 | 195 |
| Receivables | – | 4,466 | 4,817 | 5,746 | 7,094 |
| Inventory | – | 8,511 | 9,808 | 10,544 | 12,053 |
| Payables | – | 3,871 | 4,454 | 4,189 | 5,567 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 5,016 | 2,387 | 2,435 | 3,925 | 5,526 |
| Cash from investing | -3,215 | -3,978 | -4,256 | -1,875 | -3,458 |
| Cash from financing | -2,969 | 1,814 | 800 | 120 | -1,269 |
| Capex | 2,705 | 2,720 | 3,562 | 2,520 | 3,105 |
| Free cash flow | 2,312 | -334 | -1,127 | 1,405 | 2,422 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 7.2% | 10.6% | 10.7% | 9.2% |
| ROCE % | – | 8.7% | 13.0% | 13.7% | 12.1% |
| Debtor days | – | 66 | 61 | 66 | 77 |
| Inventory days | – | 275 | 284 | 295 | 326 |
| Payable days | – | 125 | 129 | 117 | 151 |
| Cash conversion cycle (days) | – | 216 | 216 | 244 | 252 |
| Working capital days | – | 148 | 146 | 144 | 159 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 51.88% |
| FIIs | 17.41% |
| DIIs | 24.42% |
| of which Mutual funds | 16.31% |
| of which Insurance | 4.84% |
| Public (non-institutions) | 6.29% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.88% | 51.88% |
| Promoter group | % |
|---|---|
| RPR Sons Advisors Private Limited, Mrs.p.suneela Rani (Jointly Holding) | 33.54% |
| Kambam Nithyananda Reddy | 4.37% |
| Kirthi Reddy Kambam | 3.46% |
| Venkata Ramprasad Reddy Penaka | 3.07% |
| Axis Clinicals Limited, Trident Chemphar Limited, RPR Sons Advisors PVT.LTD. (Jointly Holding) | 2.86% |
| Meenakshisunderam Sivakumaran | 2.48% |
| Kambam Spoorthi | 1.20% |
| Kottamanchi Rajeswari | 0.31% |
| M Sumanth Kumar Reddy | 0.27% |
| Trident Chemphar Limited | 0.13% |
| Axis Clinicals Limited | 0.11% |
| Prasada Reddy Kambham | 0.05% |
| Suneela Rani Penaka | 0.02% |
| Kambam Surya Prakash Reddy | 0.00% |
| Penaka Neha Reddy | 0.00% |
| Public holders above 1% | % |
|---|---|
| Quant Mutual Fund - Quant Arbitrage Fund | 4.91% |
| SBI Nifty Midcap 150 Index Fund | 3.51% |
| HDFC Mutual Fund-hdfc Arbitrage Fund | 3.22% |
| Life Insurance Corporation of India | 2.85% |
| NPS Trust A/C - SBI Pension Fund - UPS - CG Schem | 2.80% |
2,33,737 shareholders. Pledged: 11.99% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| LUPIN | ₹89,616 cr | 16.2x | 4.0x | 27.9% | 27.9% | 30.0% | +18.9% | 0.61% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-04-17 | Buyback | Buy Back |
| 2025-08-08 | Dividend | Interim Dividend - Rs 4 Per Share |
| 2024-08-26 | Other | Annual General Meeting |
| 2024-07-30 | Buyback | Buy Back |
| 2024-02-20 | Dividend | Interim Dividend - Rs 1.50 Per Share |
| 2023-11-20 | Dividend | Interim Dividend - Rs 3 Per Share |
| 2023-08-22 | Other | Annual General Meeting |
| 2023-02-17 | Dividend | Interim Dividend - Rs 3 Per Share |
| 2022-07-27 | Other | Annual General Meeting |
| 2022-06-06 | Dividend | Interim Dividend - Rs 4.50 Per Share |
| 2022-02-18 | Dividend | Interim Dividend - Rs 1.50 Per Share |
| 2021-11-17 | Dividend | Interim Dividend - Rs 1.50 Per Share |
| 2021-08-27 | Dividend | Interim Dividend - Rs 1.50 Per Share |
| 2021-08-20 | Other | Annual General Meeting |
| 2021-02-22 | Dividend | Interim Dividend - Rs 1.50 Per Share |
| 2020-11-23 | Dividend | Interim Dividend - Rs 1.25 Per Share |
| 2020-08-21 | Dividend | Annual General Meeting/Interim Dividend - Rs 1.25 Per Share |
| 2020-02-17 | Dividend | Interim Dividend - Rs 1.75 Per Share |
| 2019-11-21 | Dividend | Interim Dividend - Rs 1.25 Per Share |
| 2019-08-21 | Other | Annual General Meeting |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Manufacturing: Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | AUROPHARMA |
| BSE code | 524804 |
| ISIN | INE406A01037 |
| Face value | ₹1.0 |
| Incorporated | 1986-12-26 |
| Website | www.aurobindo.com |
| Plants (India / abroad) | 28 / 5 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.